Oxaliplatin + Irinotecan + Leucovorin + 5-Fluorouracil + Capecitabine + S-1 combination

This entry describes a hypothetical combination regimen consisting of oxaliplatin, irinotecan, leucovorin, 5-fluorouracil (5-FU), capecitabine, and S-1. Based on available search results, this specific six-drug combination is not a standard or documented chemotherapy regimen. Standard regimens for conditions like metastatic colorectal cancer typically involve subsets of these drugs, such as FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan) or XELOXIRI (capecitabine, oxaliplatin, irinotecan). Capecitabine and S-1 are both oral fluoropyrimidines that act as prodrugs for 5-FU and are generally used *instead* of intravenous 5-FU, not in addition to it or each other within the same regimen. The co-inclusion of intravenous 5-FU, oral capecitabine, and oral S-1 in a single regimen is highly unusual and not supported by clinical literature found.